Overview of Sanofi's Recent Annual General Meeting
The Annual General Meeting (AGM) held by Sanofi has brought forth numerous important resolutions. The gathering was led by Frédéric Oudéa, who ensured a smooth discussion and efficient voting process.
Key Resolutions Approved
During the AGM, the shareholders enthusiastically approved the financial statements for the fiscal year 2024. This included the endorsement of an ordinary cash dividend of €3.92 per share, which is set to be disbursed on May 14, 2025.
Dividend Distribution Details
This dividend marks a significant milestone for the company, reflecting its solid financial performance and commitment to returning value to its shareholders. The timely distribution underscores Sanofi's dedication to its financial obligations.
Board of Directors' Renewal
The AGM also saw the renewal of four Board members: Carole Ferrand, Barbara Lavernos, Emile Voest, and Antoine Yver. Additionally, Jean-Paul Kress was confirmed through cooptation, further enhancing the board's strategic direction.
Board Composition and Independence
The Board of Directors is currently composed of 16 members, featuring two employee representatives. Impressively, it has achieved a high independence rate of 78% and a gender diversity ratio of 43%. Notably, half of the directors hold foreign nationality, reflecting the company's global outlook and multicultural ethos.
Leadership Changes
Highlighting the commitment to good governance, the Board appointed Clotilde Delbos as Chairwoman of the Compensation Committee. This move not only strengthens leadership but also enhances oversight of the company’s compensation strategy.
Access to Meeting Highlights
Those interested in reviewing the voting results and other key moments can find a record of the meeting available for viewing, showcasing Sanofi's transparency and accountability in its corporate governance practices.
About Sanofi
Sanofi is recognized as a dynamic player in the global healthcare sector, striving to improve lives through innovative treatments. Its mission is centered on applying scientific advancements to create profound changes in medicine. By prioritizing sustainability and social responsibility, the company endeavors to provide life-altering therapeutics and essential vaccines to millions worldwide.
Investor Relations Contact Information
For those seeking further information regarding Sanofi's financial performance or developments, the investor relations team is available for inquiries. Key contacts include:
- Thomas Kudsk Larsen: +44 7545 513 693 | thomas.larsen@sanofi.com
- Alizé Kaisserian: +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
- Felix Lauscher: +1 908 612 7239 | felix.lauscher@sanofi.com
- Keita Browne: +1 781 249 1766 | keita.browne@sanofi.com
- Nathalie Pham: +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Frequently Asked Questions
What were the key decisions made during the AGM?
The AGM approved the financial statements for 2024 and a cash dividend of €3.92 per share, along with the renewal of board members.
Who was renewed in the Board of Directors?
The renewed members are Carole Ferrand, Barbara Lavernos, Emile Voest, and Antoine Yver, with Jean-Paul Kress being co-opted into the board.
What is the current composition of the Board of Directors?
The board comprises 16 Directors, including two employee representatives, with a 78% independence rate and a 43% gender diversity rate.
When will the cash dividend be distributed?
The cash dividend of €3.92 per share is set to be paid on May 14, 2025.
How is Sanofi contributing to global healthcare?
Sanofi is committed to innovative healthcare solutions, focusing on improving lives through groundbreaking treatments and prioritizing sustainability and social responsibility.
